According to an article by Barbara Quint, an employees newsletter, Elsevier Today, made the internal announcement that end user sites, BioMedNet, ChemWeb and Elsevier Engineering will no longer be funded, with some functions migrated to the main Elsevier site. This is a strong indication that Elsevier is being impacted by the move toward open access in the scientific community and House of Commons rumblings in UK. Elsevier has long been criticized in the library world for the price of their over 1000 journals, which include titles in rarefied scientific disciplines. Typical yearly price increases have been 20% at a time when library budgets are shrinking, forcing more scrutiny of journal subscriptions, both electronic and print, and outright cancellation in many cases. In the bigger picture, the commercial viability of these end user portals is limited. Individual scientific users have very limited budgets. The corporations and academic institutions which do have the budgets, albeit constrained, offer electronic versions via an intranet, requiring authentication, not a focused public access portal. Useful as these Elsevier portals may have been to individuals, they join the dust bin of other dot com sites which lacked the right combination of business model and valuable content.